Oral TYK2 Inhibition in Atopic Dermatitis - Top-Institutions - MDSpire

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

  • By

  • Kathryn Wighton

  • February 5, 2026

  • 4 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #3

    Massachusetts General Hospital (MGH) Dermatology
    Massachusetts General Hospital (MGH) Dermatology

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunodermatology

  • #4

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #5

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

Original Source(s)

Oral TYK2 Inhibition in Atopic Dermatitis

  • by Kathryn Wighton

  • February 5, 2026

Related Content

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations